Midstate Construction, HCEB, and Open Heart Kitchen have completed the Vineyard project in Livermore, CA, creating 24 permanent supportive housing units and a resource center to serve homeless and low-income residents with meals, shelter, and critical services, making a significant impact on the community's fight against homelessness.

Inmates at San Quentin are transforming their lives through a puppy-raising program, training service dogs that not only help people with disabilities but also foster rehabilitation and hope within the prison walls, breaking down barriers and creating a culture of learning and redemption.

Dave Peterson, Executive Vice President of Keegan & Coppin, has been named Basin Street Properties' Broker of the Quarter for his exceptional contributions to real estate and the community, with a $1,500 donation made in his honor to send underprivileged children to summer camp—underscoring his commitment to both professional excellence and philanthropy.

In a surprising reunion, MarinHealth and UCSF Health have teamed up with local physicians to co-own Marin Specialty Surgery Center, marking a significant shift in outpatient surgery services that promises to expand capacity and improve patient care in Marin County—just after years of separation and pandemic challenges.

Dominican University of California has unveiled its $8 million Center for the Dominican Experience, transforming a 1960s library into a cutting-edge student services hub designed to foster community engagement, inclusivity, and a more holistic college experience—an exciting step forward for students and faculty alike.

Kaiser Permanente is leading the charge in sustainable healthcare, from achieving carbon-neutral status to building net-zero energy facilities, all while addressing the growing health risks posed by climate change—an urgent mission that could reshape the future of patient care.

Ultragenyx reveals promising interim Phase 1/2 data showing rapid, multi-domain improvements in patients with Angelman syndrome treated with GTX-102, offering new hope for a disease that currently lacks any approved treatment—find out more about these groundbreaking results and what’s next in their development.